DOI : 10.1055/s-00000054

Pharmacopsychiatry

Issue 03 · Volume 53 · May 2020 DOI: 10.1055/s-010-48404

TDM-Gruppe der AGNP
XIVth Symposium of the Task Force Therapeutic Drug Monitoring of the AGNP
Mannheim, Germany, 13.05 - 15.05.2020

Due to safety considerations in connection with the spread of SARS-CoV-2, this meeting was cancelled. It may be held at a later date, please check the AGNP website for updates.

Organizing committee: Gerhard Gründer, Xenia Hart Program committee: Gerhard Gründer / Chairman Niels Bergemann, Karin Egberts, Ekkehard Haen, Ursula Havemann-Reinecke, Gudrun Hefner, Christoph Hiemke, Andreas Menke, Rainald Mössner, Florian Ridders, Georgios Schoretsanitis
Abstracts (HTML) Abstracts (PDF) List of Authors
Adamovic, I; Michaelis, S; Streit, F; Binder, L; Degner, D: 1 Case report: Major depression and Therapeutic Drug Monitoring in patient with CYP2C19 genetic polymorphism
Adamovic, I; Vierke, C; Boettcher, M; Hiemke, C; Havemann-Reinecke, U: 2 Drug interactions in patients undergoing opioid maintenance therapy
Augustin, M: 3 Therapeutic Drug Monitoring of antiepileptics and mood stabilizers in pregnancy and lactation
Baumann, P; Nil, R: 4 Slow-drop infusion versus oral administration of citalopram: Comparison of plasma concentrations of the enantiomers of citalopram and its metabolites
Buspavanich, P; Hindinger, C; Ricken, R; Adli, M; Ulrich, S: 5 Course of tranylcypromine enantiomer plasma concentrations in patients with depression
Egberts, K; TDM-VIGIL-Consortium; Plener, P; Fekete, S; Taurines, R; Gerlach, M; Romanos, M: 6 A multicenter pharmacovigilance study on antidepressant and antipsychotic use in children and adolescents in daily clinical practice
Endres, K; Haen, E: 7 The dose-related reference range – a new approach with improved predictive quality
Fekete, S; Scherf-Clavel, M; Gerlach, M; Romanos, M; Kittel-Schneider, S; Unterecker, S; Egberts, K: 8 Serum concentrations of venlafaxine and risperidone and their metabolites from childhood to old age
Geiben, A; Haen, E: 9 Influence of comedication on amitriptyline underscore the necessity of TDM
Hart, XM; Gründer, G; Hiemke, C: 10 How valid are therapeutic reference ranges for psychotropic drugs?
Hefner, G: 11 Psychopharmacotherapy in geriatric patients
Kiefer, F; Bekier, NK; Hiemke, C: 12 Therapeutic Drug Monitoring in the relapse prevention treatment of alcohol dependence
Kittel-Schneider, S; Preis, K; van Braam, L; Unterecker, S: 13 Therapeutic drug monitoring in pregnancy and post-partum period – antidepressant substances
Kneller, LA; Hempel, G: 14 Physiologically based pharmacokinetic modelling of risperidone and 9-hydroxyrisperidone to determine cytochrome P450 2D6 phenotypes in schizophrenia patients
Lipecki, Y; Haen, E: 15 A HPLC-UV/VIS method for the quantification of valproic acid in human serum
Lücht, UR; Geiben, AK; Brune, S; Scholz, WU; Hempel, G: 16 Using physiologically based pharmacokinetic (PBPK) modelling and SCHOLZ databank’s MDDI calculator (SDB-MDDI) to predict potential drug-drug interactions (DDI) of psychopharmaceuticals
Molden, E: 17 Using TDM data to study treatment failure
Nierychlewski, K; Meinzer, S; Musil, R; Schwarz, M: 18 Optimizing Therapeutic Drug Monitoring (TDM) of mirtazapine – Next step to personalized medicine
Oster, O; Ruppert, K; Schulz, E; Fleischhaker, C; Clement, HW: 19 Therapeutic Reference Ranges of Cariprazine and Atomoxetine
Roll, SC: 20 The relevance of TDM in opiate withdrawal
Scherf-Clavel, M; Breisinger, S; Fischer, M; Deckert, J; Unterecker, S; Rittner, HL: 21 Therapeutic drug monitoring of antidepressants in chronic pain treatment
Schoretsanitis, G; Haen, E; Hiemke, C; Gründer, G; Paulzen, M: 22 Using TDM to improve efficacy and safety outcomes of antipsychotic treatment
Shipkova, M: 23 Liquid Chromatography/Tandem Mass Spectrometry (LC-MSMS) Analysis of neuropsychiatric drugs: Challenges from the perspective of the laboratory physician
Stern, M; Giebels, M; Fey, T; Lübking, M; Alferink, J; Hempel, G: 24 Clinical validation study to derive conversion factors from capillary blood concentration to plasma concentration for venlafaxine and desvenlafaxine
Stingl, JC: 25 Pharmacogenetic diagnostics and therapeutic implications for genome medicine
Toto, S; Grohmann, R; Bleich, S: 26 Current data from the AMSP Project on the risk of treatment with antidepressants and antipsychotics within the clinical setting
Zurek, G: 27 Comparative study of suggested reference values and observed distributions in daily routine of a medical laboratory – lessons learned and open questions